# Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism

> **NCT02604238** · PHASE3 · WITHDRAWN · sponsor: **Azienda U.S.L. 1 di Massa e Carrara**

## Conditions studied

- Pulmonary Embolism

## Interventions

- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT02604238
- **Lead sponsor:** Azienda U.S.L. 1 di Massa e Carrara
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-03
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2024-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02604238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02604238, "Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02604238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*